Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

VBI Vaccines, Inc. - Ordinary Shares (NQ: VBIV )

0.0653 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about VBI Vaccines, Inc. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
VBI Vaccines Reveals Updated Overall Survival Data From Brain Cancer Vaccine Trial
VBI Vaccines Inc (NASDAQ: VBIV) has presented updated 12-month and 18-month overall survival (OS) data from the Phase 2a study of VBI-1901, the Company's... 
Via Benzinga
VBI Vaccines to Present New Overall Survival Data from Phase 2a Study in Recurrent GBM at the World Vaccine & Immunotherapy Congress 2021
From VBI Vaccines Inc.
Via Business Wire
BYSI Stock Alert: Bad News From the FDA Has BeyondSpring Tanking Today
BeyondSpring is falling hard after the FDA turned down a once-promising drug candidate. Here's why you shouldn't write off BYSI stock. 
Via InvestorPlace
Exposures Product Safety
Nubank IPO: 12 Things for Potential Investors to Know About the Buffett-Backed Brazilian Fintech
Nubank is in the news today as investors discuss new details from the fintech company's filing for an initial public offering (IPO). 
Via InvestorPlace
Topics Initial Public Offering
Exposures Securities Market
OP Stock: 13 Things for OceanPal Investors to Know About the Diana Shipping Spinoff as Shares Soar
OceanPal (OP) stock is riding higher Wednesday on the wave of its public debut yesterday after a spinoff from Diana Shipping (DSX)! 
Via InvestorPlace
VBIV Stock Is Shooting Higher on Big FDA Vaccine Approval News
VBI Vaccines just got the green light from the FDA for its new Hepatitis B vaccine. VBIV stock is reacting well so far today. 
Via InvestorPlace
Exposures Product Safety
FDA Approves VBI Vaccines' 3-Antigen Hepatitis B Vaccine
The FDA has approved VBI Vaccines Inc's (NASDAQ: VBIV) PreHevbrio [Hepatitis B Vaccine (Recombinant)] to prevent the infection caused by all known subtypes of... 
Via Benzinga
Exposures Product Safety
VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week. 
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses... 
Via Benzinga
Exposures COVID-19 Product Safety
VBI Vaccines to Participate in Jefferies London Healthcare Conference
From VBI Vaccines Inc.
Via Business Wire
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
VBI Vaccines Announces Third Quarter 2021 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
VBI Vaccines Announces e-Poster Presentation of 3-Antigen Prophylactic Hepatitis B Vaccine Data at The Liver Meeting® 2021
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, CONSTANT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Journal of the American Medical Association Network Open
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Participate in Upcoming Investor Conferences
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Second Quarter 2021 Financial Results and Provides Corporate Update
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Appoints Linda Bain to Board of Directors
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports New CPT Code Issued for a 3-Antigen Prophylactic Hepatitis B Vaccine
From VBI Vaccines Inc.
Via Business Wire
Why Shares of VBI Vaccines Soared, and Then Fell 7%, on Tuesday
Investors almost seemed ready to take profits once shares hit their highest level since February. 
Via The Motley Fool
Exposures COVID-19
VBI Vaccines Stock Is Trading Higher On Encouraging Data From COVID-19 Vaccine Candidate Trial
VBI Vaccines Inc (NASDAQ: VBIV) has announced positive Phase 1 data from its Phase 1/2 trial evaluating its enveloped virus-like particle (eVLP) COVID-19 vaccine... 
Via Benzinga
Exposures COVID-19
VBI Vaccines Announces Initial Positive Phase 1 Data for Its eVLP Vaccine Candidate Against COVID-19
From VBI Vaccines Inc.
Via Business Wire
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
From Brii Biosciences
Via Business Wire
VBI Vaccines to Present at Upcoming Scientific Conferences
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Results of Annual General Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021
From VBI Vaccines Inc.
Via Business Wire
Why Agenus Stock Is Jumping Today
There was some positive news, but it probably wasn't a huge catalyst for the stock. 
Via The Motley Fool
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.